Evidence map›Paper›PMID 30140982›Full record

SynthesisDigestive diseases and sciences2018

Efficacy of Nucleoside Analogs for Chronic Hepatitis B Virus-Related Hepatocellular Carcinoma After Curative Treatment: A Meta-Analysis.

Guangcong Zhang, Xiangnan Yu, Peng Liu, Xiaoxi Huang, Xuemei Jiang

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Digestive diseases and sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Hepatitis B Before and After Hepatocellular Carcinoma.Journal of gastrointestinal cancer · 2021
    Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Guangcong ZhangDepartment of Gastroenterology, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, 43 People's Avenue, Haikou, 570028, China.
Xiangnan YuDepartment of Gastroenterology, Zhongshan Hospital of Fudan University, 180 Fenglin Rd., Shanghai, 200032, China.
Peng LiuDepartment of Gastroenterology, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, 43 People's Avenue, Haikou, 570028, China.
Xiaoxi HuangDepartment of Gastroenterology, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, 43 People's Avenue, Haikou, 570028, China.
Xuemei JiangDepartment of Gastroenterology, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, 43 People's Avenue, Haikou, 570028, China. jiang.xm18@foxmail.com.ORCID http://orcid.org/0000-0001-6945-229X
Central South University · CNFudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimThe efficacy of nucleoside analogs (NAs) for hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) after curative treatment remains unclear. The present study aimed to evaluate the efficacy of these agents by conducting a comprehensive meta-analysis of available studies.

methodsWe searched several databases including Pubmed, Embase, Cochrane Library, Clinical Trials, and Web of Science, according to PRISMA guidelines. We considered all randomized controlled trials and cohort studies that met the inclusion criteria. Statistical analyses were conducted using Review Manager 5.3 and Stata 14.0.

resultsTwenty-one studies with 8752 participants were included in the final analysis. The pooled data showed that patients treated with NAs had significantly lower 1- and 3-year HCC recurrence rates (relative risk [RR] 0.76, 95% confidence interval [CI] 0.65-0.90; P = 0.001 and RR 0.79, 95% CI 0.71-0.88; P < 0.001, respectively), but there was no difference in 5-year recurrence rates (RR 0.87, 95% CI 0.74-1.03; P = 0.10). Regarding overall survival (OS), patients treated with NAs had significantly higher 1-, 3-, and 5-year OS rates (RR 1.05, 95% CI 1.02-1.08; P = 0.003; RR 1.25, 95% CI 1.16-1.34; P < 0.001; and RR 1.28, 95% CI 1.18-1.39; P < 0.001, respectively).

conclusionNA therapy has the potential to reduce the risk of early recurrence and improve OS in patients with HBV-related HCC after curative treatment, compared with placebo or no treatment. Further research including more homogeneous studies with large sample sizes is required to improve the reliability of these conclusions.

Indexed as

Carcinoma, HepatocellularHepatitis B, ChronicHumansLiver NeoplasmsNucleosidesTreatment OutcomeNucleosidesCurative treatmentHepatocellular carcinomaMeta-analysisNucleoside analog

Identifiers

PMID30140982
OpenAlexW2888462695

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.